Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Apnimed Inc. is raising $25,575,714.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Lawrence Miller played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Apnimed Inc.

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders. Our trials evaluate safety and efficacy of our novel drug candidates with the hope of addressing important unmet needs for these conditions.

To learn more about Apnimed Inc., visit http://apnimed.com/

Contact:
Lawrence Miller, President and Chief Executive Officer
617-500-8880
https://www.linkedin.com/in/lawrence-miller-9b652b10/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved